Sartorius AG
XETRA:SRT

Watchlist Manager
Sartorius AG Logo
Sartorius AG
XETRA:SRT
Watchlist
Price: 172.6 EUR -1.93%
Market Cap: 12.9B EUR
Have any thoughts about
Sartorius AG?
Write Note

Sartorius AG
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sartorius AG
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius AG
XETRA:SRT
Other Long-Term Assets
€85.9m
CAGR 3-Years
18%
CAGR 5-Years
25%
CAGR 10-Years
11%
Carl Zeiss Meditec AG
XETRA:AFX
Other Long-Term Assets
€98.1m
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
6%
Stratec SE
XETRA:SBS
Other Long-Term Assets
€3.3m
CAGR 3-Years
24%
CAGR 5-Years
30%
CAGR 10-Years
15%
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Other Long-Term Assets
€14.4m
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
-3%
Siemens Healthineers AG
XETRA:SHL
Other Long-Term Assets
€1.1B
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Other Long-Term Assets
€272.8m
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
7%
No Stocks Found

Sartorius AG
Glance View

Market Cap
11.9B EUR
Industry
Health Care

Sartorius AG, a formidable player in the life sciences industry, has been weaving the fabric of innovation within the biotechnology sector for over a century. Originating in 1870 as a precision mechanics workshop in Göttingen, Germany, the company has blossomed into a global powerhouse in the biopharmaceutical and laboratory equipment market. Central to Sartorius's operations is its focus on providing cutting-edge solutions that streamline lab processes and enhance productivity. By offering essential products like bioreactors and cell culture media, Sartorius plays a pivotal role in accelerating research and production processes for pharmaceutical companies worldwide. Underpinning Sartorius's financial success is its dual-pronged strategy: the Bioprocess Solutions division and the Lab Products & Services division. The Bioprocess Solutions wing caters to the production needs of biopharmaceuticals, delivering equipment and technologies crucial for manufacturing therapies and vaccines. Meanwhile, the Lab Products & Services division offers an array of instruments and consumables pivotal for research and quality control. This strategic alignment allows Sartorius to maintain robust growth by capturing value from both research and industrial production stages in biotech. With a well-orchestrated focus on innovation and expansion, Sartorius has cemented its role as a critical enabler in the biopharmaceutical value chain, continually driving developments that shape the future of medicine.

SRT Intrinsic Value
184.25 EUR
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Sartorius AG's Other Long-Term Assets?
Other Long-Term Assets
85.9m EUR

Based on the financial report for Sep 30, 2024, Sartorius AG's Other Long-Term Assets amounts to 85.9m EUR.

What is Sartorius AG's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
11%

Over the last year, the Other Long-Term Assets growth was 9%. The average annual Other Long-Term Assets growth rates for Sartorius AG have been 18% over the past three years , 25% over the past five years , and 11% over the past ten years .

Back to Top